Longboard Pharmaceuticals’ Post

Today, we announced that the U.S. FDA has granted Breakthrough Therapy designation for bexicaserin for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) for patients two years of age or older. We are so happy to share this tremendous milestone and excited for the potential implications for the DEE community! https://bit.ly/3XLGnQX

We’re proud to stand with the Dravet syndrome community, especially today for International Dravet Syndrome Awareness Day. This weekend we met with families at the Dravet Syndrome Foundation Biennial Family & Professional Conference, and had the opportunity to learn more about the joys and hardships families and their Dravet warriors face living with this Developmental and Epileptic Encephalopathy. It was an honor to present and participate at this conference, and to interact with everyone there!

Thank you to Life Science Cares San Diego and our Longboard team members that volunteered at Feeding San Diego last week. Great teamwork for a great cause!

Today, we raise awareness for CDKL5 Deficiency Disorder, a rare genetic condition causing developmental and epileptic encephalopathy and early-onset seizures. Last week our team had the privilege of spending time with this amazing community at the International Foundation for CDKL5 Research (IFCR) 6th Annual Conference, where families, clinicians, industry and researchers came together to celebrate success and work towards an even better future for individuals living with #CDKL5. #CDKL5Awareness #CDKL5Forward

Today, we announced positive interim results from our ongoing 52-week open-label extension (OLE) of the PACIFIC Study evaluating bexicaserin (LP352) in participants ages 12-65 years old with Developmental and Epileptic Encephalopathies (DEEs). Additional detail can be found in our press release https://bit.ly/4efEgKU & OLE presentation https://bit.ly/3OEgIEd.

Great week in Boston at the The Association of Bioscience Financial Officers International 2024 Conference! Brandi Roberts, Longboard's CFO, participated in the CFO Best Practices panel. #ABFO #ABFO2024

We look forward to attending #BIO2024 in our hometown of San Diego next week! If you are interested in meeting with our team, please contact us at Info@longboardpharma.com.

We are #hiring! Check out our open positions here: https://bit.ly/3OHvOsQ #DataManagment #DrugSafety #CRA #CTA #ClinicalDevelopment #SeniorScientist #ADME